EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Comprehensive Genome Profiling‐Initiated Tumor‐Informed Circulating Tumor DNA Monitoring for Patients With Advanced Cancer

Taiga Sasaki iD, Hayato Hiraki, Akiko Yashima-Abo, Hiromi Nagashima, Fumitaka Endo, Mizunori Yaegashi, Shimpei Miura, Keiko Obata, Naoki Yanagawa, Hiroaki Itamochi iD, Hidekazu Shirota iD, Takeshi Iwaya und 1 weitere

Cancer Science · 2025-03 · 116 (3) · 764-774

DOI: 10.1111/cas.16446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 05.01.2025. Verfasst von Taiga Sasaki und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biomedical Research and Development, Iwate Medical University Institute for Biomedical Sciences, Yahaba, Japan. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In Japan, comprehensive genome profiling (CGP) as a companion diagnostic (CDx) has been covered by public insurance since June 2019, but the proportion of patients with cancer who actually received drug therapy based on CGP data is low. In the present study, we attempted to use CGP as a starting point for tumor‐informed circulating tumor DNA (ctDNA) monitoring. We retrospectively validated 219 patients with malignant tumors who underwent CGP at Iwate Medical University Hospital between October 2019 and April 2023 in terms of patient demographics, genetic analysis, drug recommendations, and drug administration rate. The 219 cancer cases analyzed by CGP for 27 target organs, including prostate ( n = 27, 12.3%), colorectal ( n = 25, 11.4%), lung ( n = 19, 8.7%), and other neoplasms ( n = 148, 67.6%). Among the cohort, only 14 cases (6.4%) subsequently were able to undertake the recommended action by Molecular Tumor Board. Of patients who underwent ctDNA monitoring based on somatic mutations identified by CGP ( n = 11), clinical validity was confirmed in terms of early relapse prediction ( n = 5, 45.5%), treatment response evaluation ( n = 10, 90.9%), and no relapse/regrowth corroboration ( n = 2, 18.2%) whereas 90.9% ( n = 10) of patients obtained information with at least one source of the clinical validity. Although the current rate of CGP contributing to a drug recommendation is low, CGP results can be an alternate resource for tumor‐informed longitudinal ctDNA monitoring to provide information concerning early relapse prediction, treatment response evaluation, and no relapse/regrowth corroboration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNANeoplasmsBiomarkers, TumorHumansMaleFemaleAgedMiddle AgedRetrospective StudiesMutationAged, 80 and overAdultJapan

Stichwörter der Autor:innen

Digital PCRcomprehensive genome profilingtumor‐informed ctDNA monitoring

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Biomedical Research and Development, Iwate Medical University Institute for Biomedical Sciences, Yahaba, Japan.
  • Department of Respiratory Medicine, Iwate Medical University School of Medicine, Yahaba, Japan.
  • Department of Clinical Oncology, Iwate Medical University School of Medicine, Yahaba, Japan.
  • Department of Surgery, Iwate Medical University School of Medicine, Yahaba, Japan.
  • Department of Dermatology, Iwate Medical University School of Medicine, Yahaba, Japan.
  • Department of Clinical Genetics, Iwate Medical University School of Medicine, Yahaba, Japan.

ORCID-Profile: Taiga Sasaki, Hiroaki Itamochi, Hidekazu Shirota, Satoshi S Nishizuka

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Sasaki, T., Hiraki, H., Yashima-Abo, A., Nagashima, H., Endo, F., Yaegashi, M., Miura, S., Obata, K., Yanagawa, N., Itamochi, H., Shirota, H., Iwaya, T., & Nishizuka, S. S. (2025). Comprehensive Genome Profiling‐Initiated Tumor‐Informed Circulating Tumor DNA Monitoring for Patients With Advanced Cancer. Cancer Science, 116(3), 764-774. https://doi.org/10.1111/cas.16446

Vancouver

Sasaki T, Hiraki H, Yashima-Abo A, Nagashima H, Endo F, Yaegashi M, et al. Comprehensive Genome Profiling‐Initiated Tumor‐Informed Circulating Tumor DNA Monitoring for Patients With Advanced Cancer. Cancer Science. 2025;116(3):764-774. doi:10.1111/cas.16446

BibTeX
@article{Sasaki2025,
  author = {Sasaki, Taiga and Hiraki, Hayato and Yashima-Abo, Akiko and Nagashima, Hiromi and Endo, Fumitaka and Yaegashi, Mizunori and Miura, Shimpei and Obata, Keiko and Yanagawa, Naoki and Itamochi, Hiroaki and Shirota, Hidekazu and Iwaya, Takeshi and Nishizuka, Satoshi S},
  title = {Comprehensive Genome Profiling‐Initiated Tumor‐Informed Circulating Tumor DNA Monitoring for Patients With Advanced Cancer},
  journal = {Cancer Science},
  year = {2025},
  volume = {116},
  number = {3},
  pages = {764--774},
  doi = {10.1111/cas.16446}
}
Kostenlos starten →